Anti-PCSK9 antibody
Specifications
| Product type: | Primary antibody |
| Antigen: | PCSK9 |
| Immunogen: | Recombinant protein |
| Species immunized: | Mouse |
| Isotype: | IgG2b |
| Applications: | Immunohistochemistry (1:100); Immunocytochemistry (1:100-1:200); Flow Cytometry (1:100-1:200) |
| Reactivity: | Human, Mouse |
| Clonality (clone number): | Monoclonal(2F2) |
| Form: | Liquid |
| Buffer: | 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. |
| Concentration: | 2mg/ml |
| Purity: | Protein A affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | Convertase subtilisin/kexin type 9 preproprotein antibody |
| FH3 antibody | |
| HCHOLA3 antibody | |
| Hypercholesterolemia autosomal dominant 3 antibody | |
| LDLCQ1 antibody | |
| NARC 1 antibody | |
| NARC-1 antibody | |
| NARC1 antibody | |
| Neural apoptosis regulated convertase 1 antibody | |
| Neural apoptosis-regulated convertase 1 antibody | |
| PC 9 antibody | |
| PC9 antibody | |
| PCSK 9 antibody | |
| PCSK9 antibody | |
| PCSK9_HUMAN antibody | |
| Proprotein convertase 9 antibody | |
| Proprotein convertase PC9 antibody | |
| Proprotein convertase subtilisin/kexin type 9 antibody | |
| PSEC0052 antibody | |
| Subtilisin/kexin like protease PC9 antibody | |
| Subtilisin/kexin-like protease PC9 antibody |
Target information
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na+ channel (ENaC)-mediated Na+ absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Provider
Erpantech Laboratory
